Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1621926

Cover Image

PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1621926

Alopecia Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032

PUBLISHED:
PAGES: 135 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 4850
PDF & Excel (Multi User License)
USD 6050
PDF & Excel (Enterprise User License)
USD 8350

Add to Cart

The Global Alopecia Market was valued at USD 8.7 billion in 2023 and is anticipated to grow at a CAGR of 8.1% between 2024 and 2032. The market expansion is primarily driven by the rising prevalence of alopecia and increased awareness of available treatment options. Various factors, such as genetic predispositions, hormonal changes, autoimmune conditions, and environmental stressors, contribute to the growing number of alopecia cases. Additionally, lifestyle factors like poor diet and stress further aggravate hair loss, pushing more individuals to seek effective treatments. With millions affected by alopecia globally, the demand for both pharmaceutical treatments and advanced hair restoration technologies is on the rise.

This growing patient base propels market growth, as more people explore treatment options to combat hair loss. In terms of disease type, the market is segmented into androgenetic alopecia, alopecia areata, and other forms of hair loss. Androgenetic alopecia, commonly known as pattern baldness, accounted for the largest share in 2023, generating around USD 4.8 billion in revenue. Affecting a significant percentage of men, particularly as they age, androgenetic alopecia remains a dominant driver of market demand for treatments.

When categorized by treatment type, pharmaceuticals took the lead in 2023, claiming 48.8% of the total market share. Widely recognized for their effectiveness, pharmaceutical treatments-both topical and oral-are often the first choice for treating alopecia due to their non-invasive nature and proven ability to stimulate hair regrowth. Their accessibility and ease of use make them the most preferred option among patients. North America alopecia market, which generated USD 3.2 billion in revenue in 2023, is expected to grow at a 7.7% CAGR through 2032. The high incidence of alopecia in the region, particularly androgenetic alopecia, drives the demand for innovative and effective treatments.With a large portion of the population affected by hair loss, North America continues to be a key market contributing to overall industry growth.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$8.7 Billion
Forecast Value$17.3 Billion
CAGR8.1%
Product Code: 11643

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of alopecia
      • 3.2.1.2 Technological advancements in treatment regimes
      • 3.2.1.3 Growing awareness about alopecia treatment options
      • 3.2.1.4 Rising demand for drugs and treatments
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Regulatory barriers in treatment access
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Consumer preference
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis
  • 3.9 Future market trends
  • 3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Androgenetic alopecia
  • 5.3 Alopecia areata
  • 5.4 Other disease types

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Pharmaceutical
    • 6.2.1 Topical
    • 6.2.2 Oral
  • 6.3 Device
    • 6.3.1 Laser cap
    • 6.3.2 Laser comb
    • 6.3.3 Laser helmet
  • 6.4 Other treatments

Chapter 7 Market Estimates and Forecast, By Gender, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Male
  • 7.3 Female

Chapter 8 Market Estimates and Forecast, By Sales Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Prescription
  • 8.3 OTC

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Dermatology clinics
  • 9.3 Homecare settings
  • 9.4 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
    • 10.3.7 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
    • 10.5.4 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 Apira Science, Inc. (iGROW Laser)
  • 11.2 Aurobindo Pharma
  • 11.3 Bosley - Hair Restoration & Transplant
  • 11.4 Cipla
  • 11.5 Curallux, LLC
  • 11.6 Dr. Reddy's Laboratories Ltd.
  • 11.7 Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System)
  • 11.8 Johnson & Johnson Services, Inc.
  • 11.9 Lexington International., LLC
  • 11.10 Merck KGaA
  • 11.11 Pfizer Inc.
  • 11.12 REVIAN, Inc.
  • 11.13 Smart Graft
  • 11.14 Sun Pharmaceuticals Industries Ltd.
  • 11.15 Theradome Inc.
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!